Iris Roth - 01 Mar 2023 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role: Chief Operating Officer
Signature: /s/ Andrea Paul, attorney-in-fact for Iris Roth
Issuer symbol: ZNTL
Transactions as of: 01 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 02 Mar 2023, 15:30:11 UTC
Previous filing: 13 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZNTL	Common Stock	Award	$0	+52,500		$0.000000	52,500	01 Mar 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZNTL	Stock Option (Right to Buy)	Award	$0	+297,500		$0.000000	297,500	01 Mar 2023	Common Stock	297,500	$18.87	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of Feb. 6, 2023, subject to the Reporting Person's continuing service with the Issuer.
F2	The options will vest over four years: 25% of the options will vest on February 6, 2024, with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer.